Hypoxic radiosensitization: adored and ignored
- PMID: 17827455
- DOI: 10.1200/JCO.2007.12.7878
Hypoxic radiosensitization: adored and ignored
Abstract
Since observations from the beginning of the last century, it has become well established that solid tumors may contain oxygen-deficient hypoxic areas and that cells in such areas may cause tumors to become radioresistant. Identifying hypoxic cells in human tumors has improved by the help of new imaging and physiologic techniques, and a substantial amount of data indicates the presence of hypoxia in many types of human tumors, although with a considerable heterogeneity among individual tumors. Controlled clinical trials during the last 40 years have indicated that this source of radiation resistance can be eliminated or modified by normobaric or hyperbaric oxygen or by the use of nitroimidazoles as hypoxic radiation sensitizers. More recently, attention has been given to hypoxic cytotoxins, a group of drugs that selectively or preferably destroys cells in a hypoxic environment. An updated systematic review identified 10,108 patients in 86 randomized trials designed to modify tumor hypoxia in patients treated with curative attempted primary radiation therapy alone. Overall modification of tumor hypoxia significantly improved the effect of radiotherapy, with an odds ratio of 0.77 (95% CI, 0.71 to 0.86) for the outcome of locoregional control and with an associated significant overall survival benefit (odds ratio = 0.87; 95% CI, 0.80 to 0.95). No significant influence was found on the incidence of distant metastases or on the risk of radiation-related complications. Ample data exist to support a high level of evidence for the benefit of hypoxic modification. However, hypoxic modification still has no impact on general clinical practice.
Similar articles
-
The impact of hypoxia and its modification of the outcome of radiotherapy.J Radiat Res. 2016 Aug;57 Suppl 1(Suppl 1):i90-i98. doi: 10.1093/jrr/rrw007. Epub 2016 Mar 16. J Radiat Res. 2016. PMID: 26983987 Free PMC article. Review.
-
Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers.Semin Radiat Oncol. 1996 Jan;6(1):10-21. doi: 10.1053/SRAO0060010. Semin Radiat Oncol. 1996. PMID: 10717158
-
Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.Bull Cancer. 2008 Mar;95(3):282-91. doi: 10.1684/bdc.2008.0592. Bull Cancer. 2008. PMID: 18390408 Review.
-
Sensitization of hypoxic tumour cells--clinical experience.Int J Radiat Biol. 1989 Nov;56(5):801-11. doi: 10.1080/09553008914552081. Int J Radiat Biol. 1989. PMID: 2573679 Review.
-
Chemical modifiers of cancer treatment.J Clin Oncol. 1988 Apr;6(4):709-33. doi: 10.1200/JCO.1988.6.4.709. J Clin Oncol. 1988. PMID: 3282035 Review.
Cited by
-
Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo.Exp Ther Med. 2012 Feb;3(2):299-303. doi: 10.3892/etm.2011.389. Epub 2011 Nov 24. Exp Ther Med. 2012. PMID: 22969885 Free PMC article.
-
Uptake rate of cationic mitochondrial inhibitor MKT-077 determines cellular oxygen consumption change in carcinoma cells.PLoS One. 2012;7(5):e37471. doi: 10.1371/journal.pone.0037471. Epub 2012 May 17. PLoS One. 2012. PMID: 22616013 Free PMC article.
-
Individualization of cancer treatment from radiotherapy perspective.Mol Oncol. 2012 Apr;6(2):211-21. doi: 10.1016/j.molonc.2012.01.007. Epub 2012 Feb 9. Mol Oncol. 2012. PMID: 22381063 Free PMC article. Review.
-
Hypoxia in head and neck squamous cell carcinoma.ISRN Otolaryngol. 2012 Oct 16;2012:708974. doi: 10.5402/2012/708974. Print 2012. ISRN Otolaryngol. 2012. PMID: 23762617 Free PMC article.
-
Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response.Phys Med Biol. 2013 Jul 21;58(14):4897-919. doi: 10.1088/0031-9155/58/14/4897. Epub 2013 Jun 21. Phys Med Biol. 2013. PMID: 23787766 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources